Mount Yale Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $96.5K | Buy |
+768
| New | +$96.5K | 0.01% | 667 |
|
|
2023
Q2 | – | Sell |
-5,787
| Closed | -$586K | – | 501 |
|
|
2023
Q1 | $586K | Sell |
5,787
-721
| -11% | -$73K | 0.07% | 274 |
|
|
2022
Q4 | $777K | Sell |
6,508
-1,475
| -18% | -$176K | 0.09% | 229 |
|
|
2022
Q3 | $848K | Sell |
7,983
-215
| -3% | -$22.8K | 0.11% | 191 |
|
|
2022
Q2 | $799K | Sell |
8,198
-484
| -6% | -$47.2K | 0.1% | 202 |
|
|
2022
Q1 | $814K | Buy |
+8,682
| New | +$814K | 0.09% | 229 |
|
|
2021
Q4 | – | Sell |
-6,532
| Closed | -$626K | – | 477 |
|
|
2021
Q3 | $626K | Buy |
6,532
+48
| +0.7% | +$4.6K | 0.07% | 242 |
|
|
2021
Q2 | $631K | Buy |
6,484
+124
| +2% | +$12.1K | 0.08% | 239 |
|
|
2021
Q1 | $619K | Buy |
+6,360
| New | +$619K | 0.08% | 232 |
|
|
2020
Q4 | – | Sell |
-5,080
| Closed | -$488K | – | 413 |
|
|
2020
Q3 | $488K | Buy |
+5,080
| New | +$488K | 0.07% | 244 |
|